Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma

被引：3
|
作者：
Sheikh, Semira [1 ]
Mokhtari, Sepideh [2 ]
Silverman, Jeffrey A. [3 ]
Reid, Kayla [4 ]
Faramand, Rawan [5 ]
Davila, Marco L. [6 ]
Franke, Norman [7 ]
Locke, Frederick L. [6 ]
Jain, Michael D. [6 ]
Wong, Daniel [8 ]
Kuruvilla, John G. [7 ]
机构：
[1] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON M5G 2C1, Canada
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA
[3] North York Gen Hosp, Dept Hematol, Toronto, ON, Canada
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunol, Tampa, FL USA
[7] Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON, Canada
[8] North York Gen Hosp, Dept Neurol, Toronto, ON, Canada
来源：
EJHAEM | 2022年 / 3卷 / 01期
关键词：
CAR T cell therapy; ICANS; neurotoxicity; transverse myelitis; NEUROTOXICITY;
D O I：
10.1002/jha2.286
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：223 / 227
页数：5
相关论文
共 50 条
  • [41] Disease Control Affects Outcomes of Patients with Relapsed Diffuse Large B Cell Lymphoma Treated with CD19 Directed CAR T-Cell Therapy
    Pan, Dorothy C.
    Hamid, Showkat
    Herr, Megan
    Attwood, Kristopher
    McCarthy, Philip L.
    Ross, Maureen
    Schofield, Grant
    Cortese, Matthew J.
    Lamonica, Dominick
    Wong, Jerry Thwin
    Fu, Kai
    Maslak, Peter
    Davila, Marco
    Brentjens, Renier
    Hernandez-Ilizaliturri, Francisco J.
    BLOOD, 2023, 142
  • [42] Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy
    Chong, Elise A.
    Melenhorst, J. Joseph
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Mato, Anthony R.
    Tian, Lifeng
    Parakandi, Harit
    Lacey, Simon F.
    June, Carl H.
    Schuster, Stephen J.
    BLOOD, 2017, 130
  • [43] Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma
    Hashmi, Hamza
    Darwin, Alicia
    Bachmeier, Christina A.
    Chavez, Julio
    Shah, Bijal
    Ibarz, Javier Pinilla
    Nishihori, Taiga
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien D.
    Davila, Marco L.
    Locke, Frederick L.
    Jain, Michael D.
    BLOOD, 2019, 134
  • [44] Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy
    Jodon, Gray
    Colton, Meryl D.
    Abbott, Diana
    Cai, Anthony
    Haverkos, Bradley
    Morgan, Rustain
    Kamdar, Manali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (01): : 49 - 56
  • [45] Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
    Hashmi, Hamza
    Mirza, Abu-Sayeef
    Darwin, Alicia
    Logothetis, Constantine
    Garcia, Franco
    Kommalapati, Anuhya
    Mhaskar, Rahul S.
    Bachmeier, Christina
    Chavez, Julio C.
    Shah, Bijal
    Pinilla-Ibarz, Javier
    Khimani, Farhad
    Lazaryan, Aleksandr
    Liu, Hien
    Davila, Marco L.
    Locke, Frederick L.
    Nishihori, Taiga
    Jain, Michael D.
    BLOOD ADVANCES, 2020, 4 (17) : 4086 - 4090
  • [46] Anti-CD19 CAR T Therapy Following Autologous HSCT May be Safe and Effective in Patients with Refractory Large B-Cell Lymphoma
    Liu, Wei
    Huang, Wenyang
    Lv, Rui
    Deng, Shuhui
    Yi, Shuhua
    Qiu, Lugui
    Zou, Dehui
    BLOOD, 2019, 134
  • [47] Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma
    Kedmi, Meirav
    Shouval, Roni
    Fried, Shalev
    Bomze, David
    Fein, Joshua
    Cohen, Zachary
    Danilesko, Ivetta
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Jacoby, Elad
    Besser, Michal
    Shimoni, Avichai
    Nagler, Arnon
    Avigdor, Abraham
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (05): : 251 - 257
  • [48] Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies
    包芳
    China Medical Abstracts (Internal Medicine), 2018, 35 (03) : 186 - 187
  • [49] Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
    Sesques, Pierre
    Kirkwood, Amy A.
    Kwon, Mi
    Rejeski, Kai
    Jain, Michael D.
    Di Blasi, Roberta
    Brisou, Gabriel
    Gros, Francois-Xavier
    le Bras, Fabien
    Bories, Pierre
    Choquet, Sylvain
    Rubio, Marie-Therese
    Iacoboni, Gloria
    O'Reilly, Maeve
    Casasnovas, Rene-Olivier
    Bay, Jacques-Olivier
    Mohty, Mohamad
    Joris, Magalie
    Abraham, Julie
    Llorente, Cristina Castilla
    Loschi, Mickael
    Carras, Sylvain
    Chauchet, Adrien
    La Rochelle, Laurianne Drieu
    Hermine, Olivier
    Guidez, Stephanie
    Cony-Makhoul, Pascale
    Fogarty, Patrick
    Le Gouill, Steven
    Morschhauser, Franck
    Gastinne, Thomas
    Cartron, Guillaume
    Subklewe, Marion
    Locke, Frederick L.
    Sanderson, Robin
    Barba, Pere
    Houot, Roch
    Bachy, Emmanuel
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [50] CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma
    Olson, Michael
    Luetkens, Tim
    Iglesias, Fiorella
    Radhakrishnan, Sabarinath
    Law, Jennie Y.
    Avila, Stephanie
    Mause, Erica Vander
    Camp, Nicola J.
    Morales, Erin
    Rapoport, Aaron P.
    Dahiya, Saurabh
    Brody, Joshua
    Welm, Alana
    Atanackovic, Djordje
    BLOOD, 2021, 138
12345